The stock of NanoString Technologies Inc (NASDAQ:NSTG) is a huge mover today! About 278,729 shares traded hands or 42.55% up from the average. NanoString Technologies Inc (NASDAQ:NSTG) has risen 15.95% since April 1, 2016 and is uptrending. It has outperformed by 14.74% the S&P500.
The move comes after 6 months positive chart setup for the $380.16 million company. It was reported on Nov, 3 by Barchart.com. We have $51.26 PT which if reached, will make NASDAQ:NSTG worth $600.65M more.
Analysts await NanoString Technologies Inc (NASDAQ:NSTG) to report earnings on November, 7. They expect $-0.51 earnings per share, down 4.08% or $0.02 from last year’s $-0.49 per share. After $-0.55 actual earnings per share reported by NanoString Technologies Inc for the previous quarter, Wall Street now forecasts -7.27% EPS growth.
According to Zacks Investment Research, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington.”
Insitutional Activity: The institutional sentiment increased to 2.52 in Q2 2016. Its up 1.31, from 1.21 in 2016Q1. The ratio is positive, as 9 funds sold all NanoString Technologies Inc shares owned while 12 reduced positions. 15 funds bought stakes while 38 increased positions. They now own 16.55 million shares or 3.90% more from 15.93 million shares in 2016Q1.
Blackrock Institutional Na last reported 0% of its portfolio in the stock. Spark Invest Mgmt accumulated 115,700 shares or 0.14% of the stock. Creative Planning has 0% invested in the company for 1,802 shares. Bnp Paribas Arbitrage Sa has 576 shares for 0% of their US portfolio. Schwab Charles Investment Mgmt last reported 0% of its portfolio in the stock. State Street holds 181,377 shares or 0% of its portfolio. Nationwide Fund Advsr holds 9,064 shares or 0% of its portfolio. First Light Asset Ltd Liability Company has 0.69% invested in the company for 118,547 shares. Invesco Limited, a Georgia-based fund reported 37,118 shares. Redmile Grp Limited Liability holds 2.35% or 1.95M shares in its portfolio. Rs Ltd Com accumulated 27,050 shares or 0% of the stock. Blackrock Fund Advisors, a California-based fund reported 639,372 shares. Geode Capital Management Ltd holds 0% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG) for 88,618 shares. Foresite Cap Ii Ltd Com has 727,857 shares for 6.27% of their US portfolio. Polar Ltd Liability Partnership has invested 0.02% of its portfolio in NanoString Technologies Inc (NASDAQ:NSTG).
Insider Transactions: Since August 12, 2016, the stock had 0 buys, and 7 selling transactions for $9.39 million net activity. BURNS WAYNE sold $65,357 worth of stock. On Friday, August 26 the insider WAITE CHARLES P JR sold $1.84 million.
Another recent and important NanoString Technologies Inc (NASDAQ:NSTG) news was published by Quotes.Wsj.com which published an article titled: “News NanoString Technologies Inc.NSTG” on June 26, 2013.
NSTG Company Profile
NanoString Technologies, Inc., incorporated on June 20, 2003, develops, makes and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Firm operates in the segment of development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. The Company’s nCounter Analysis System is an automated, multi-application, digital detection and counting system, which directly profiles hundreds of molecules simultaneously using a barcoding technology. The Firm markets systems and related consumables to researchers in academic, government and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of diseases, such as cancer, and to clinical laboratories and medical centers for diagnostic use. The Company’s molecular diagnostic product Prosigna Breast Cancer Assay, or Prosigna, provides an assessment of a patient’s risk of recurrence for breast cancer. The Firm has an installed base of over 350 systems, which its clients have used to publish more than 1,000 peer-reviewed papers.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.